Media & Resources

Filter by

  • Type

  • Health area

  • Location

  • Topic

  • Year

  • Journal

  • Publication

  • Fact sheet & publication type

  • Clear all

IAVI Report

What next? HIV science (again) at a turning point

December 20, 2021

After four decades of HIV research, the field seeks to make progress against one of the most difficult pathogens vaccine researchers have ever faced.

Read more

IAVI Report

Vaccinology reaches a new peak

December 20, 2021

Stanley Plotkin discusses the greatest progress in vaccine development in more than half a century and the lingering barriers to an effective HIV vaccine.

Read more

IAVI Report

The global stakes for vaccine access

December 20, 2021

COVID-19 has made stark inequities in global access to vaccines, drugs, and diagnostics more visible and alarming than ever.

Read more

Podcasts

Inside IAVI: In conversation with Seth Berkley & Mark Feinberg

December 6, 2021

In conversation with Seth Berkley & Mark Feinberg: 25 years of innovation, partnerships, and access As we mark  25 years of IAVI,  we’re  inviting our current President and CEO, Mark...
Read more

Press Releases

GreenLight (ENVI) and IAVI begin work on Omicron variant-adapted COVID-19 vaccine candidate

December 3, 2021

BOSTON and NEW YORK – DECEMBER 3, 2021 – GreenLight Biosciences (ENVI) and IAVI, a non-profit scientific research organization, today announced work on a messenger RNA vaccine candidate to tackle the COVID-19 Omicron variant. “The highly mutated Omicron variant may be partially capable of eluding existing vaccines, so rapid adaptation is an urgent priority,” said…

Read more

In The News

WHO recommends malaria vaccine for children

The Lancet

December 1, 2021

Read more

Press Releases

GreenLight Biosciences (ENVI) partners with IAVI to accelerate COVID-19 vaccine trial in Africa

November 30, 2021

IAVI’s extensive clinical trial experience will be combined with GreenLight COVID-19 vaccine candidate. Goal is to broaden and accelerate access to messenger RNA (mRNA) COVID-19 vaccines. Phase I trial planned for late Q1 2022. Plan speeds creation of vaccines in Africa, for Africa, and suitable for use in low-income countries globally. NEW YORK – NOVEMBER…

Read more

Scientific Publications

Abortion and its correlates among female fisherfolk along Lake Victoria in Uganda

Read more